A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin physician to discuss.

An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...